Alexandra Jobert1,2, Edouard-Jules Laforgue3,4,5, Marie Grall-Bronnec3,5, Morgane Rousselet3,4,5, Morgane Péré6, Pascale Jolliet3,4, Fanny Feuillet3, Caroline Victorri-Vigneau3,4. 1. Inserm UMR 1246, SPHERE, Methods in Patients-centered outcomes and Health Research, Nantes and Tours University, Nantes, France. alexandra.jobert@chu-nantes.fr. 2. Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, University Hospital, 5 allée de l'île gloriette, Nantes Cedex, 44093, Nantes, France. alexandra.jobert@chu-nantes.fr. 3. Inserm UMR 1246, SPHERE, Methods in Patients-centered outcomes and Health Research, Nantes and Tours University, Nantes, France. 4. Pharmacologie clinique, Centre Hospitalier Universitaire de Nantes, University Hospital, Place Alexis Ricordeau, 44093, Nantes, France. 5. Addictologie et Psychiatrie de liaison, Centre Hospitalier Universitaire de Nantes, University Hospital, Nantes, 8 hôpital Saint-Jacques 85 rue Saint-Jacques, 44093, Nantes Cedex 1, France. 6. Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, University Hospital, 5 allée de l'île gloriette, Nantes Cedex, 44093, Nantes, France.
Abstract
PURPOSE: Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated. METHOD: This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms. RESULTS: In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders. CONCLUSION: Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.
PURPOSE:Benzodiazepines (BZDs) and related drugs (Z-drugs) are mainly taken chronically, and older people are much more likely to take them on a chronic basis despite recommendations. Withdrawal symptoms could be an obstacle to stopping BZD/Z-drug administration. The main objective of this study is to estimate the prevalence of withdrawal symptoms in patients aged 65 years and older who have experience a stop of BZD/Z-drug. The secondary objectives are to describe the withdrawal symptoms and identify factors associated. METHOD: This ancillary study was based on a national observational study in patients with chronic BZD/Z-drug consumption. Patients who made at least one BZD/Z-drug stop experience were selected. Withdrawal symptoms are described, and a logistic regression was carried out to identify the variables most associated with withdrawal symptoms. RESULTS: In total, 697 patients were selected: 78% experienced at least one withdrawal symptom after a stop administering BZDs or Z-drugs; most of the withdrawal symptoms were psychological disorders. CONCLUSION: Our study identifies a specific population experiencing withdrawal symptoms and who cannot stop administering BZD/Z-drug. We assume that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.
Authors: Rajaa Lagnaoui; Bernard Bégaud; Nicholas Moore; Anicet Chaslerie; Annie Fourrier; Luc Letenneur; Jean François Dartigues; Yola Moride Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: Alexandra Jobert; Marion Istvan; Edouard-Jules Laforgue; Benoit Schreck; Caroline Victorri-Vigneau Journal: Int J Environ Res Public Health Date: 2021-11-18 Impact factor: 3.390